Articles Published in 2013

Arcturus Therapeutics acquires UNA patent estate from Marina Biotech

Friday, August 16, 2013 12:10 PM

Arcturus Therapeutics, which focuses on RNA interference (RNAi) technologies for the treatment of disease, has acquired the patented portfolio of Unlocked Nucleobase Analog (UNA) intellectual property from Marina Biotech. Financial terms of the UNA agreement were not disclosed.

More... »

NIH awards Seattle BioMed $16.6 million tuberculosis grant

Friday, August 16, 2013 12:04 PM

Seattle BioMed, a U.S. independent nonprofit focused solely on infectious disease research, has been awarded a grant from the National Institute of Allergy and Infectious Diseases, part of the NIH, which will take a comprehensive systems approach to tuberculosis (TB) infection, harnessing the power of technology and systems biology to examine the progression from latent infection to disease. The grant will total up to $16.6 million over a five-year period.

More... »

Theorem, RadMD collaborate

Friday, August 16, 2013 11:44 AM

Theorem Clinical Research is collaborating with RadMD, a medical imaging company.

More... »

ABPI launches clinical trial disclosure toolkit

Friday, August 16, 2013 11:36 AM

The Association of the British Pharmaceutical Industry (ABPI) has launched a clinical trial disclosure toolkit to help pharmaceutical companies meet clinical trial transparency requirements.

More... »

Ligand, CURx enter global license agreement

Friday, August 16, 2013 11:20 AM

Ligand Pharmaceuticals has entered a global license agreement with CURx Pharmaceuticals for the development and commercialization of Ligand's Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate. Ligand will be eligible to receive more than $21 million in potential net milestone payments and net royalties on future sales of 6.0% to 7.5%.

More... »

John Hopkins study suggests neurologists unaware of drug risks

Friday, August 16, 2013 10:41 AM

A study by Johns Hopkins researchers shows a fifth of U.S. neurologists appear unaware of serious drug safety risks associated with various anti-epilepsy drugs, potentially jeopardizing the health of patients who could be just as effectively treated with safer alternative medications.

More... »

Parthenon Capital acquires Bracket

Friday, August 16, 2013 10:15 AM

Bracket, a specialty services provider, has been acquired by Parthenon Capital Partners, a growth-oriented private equity firm based in Boston and San Francisco, from Express Scripts Holding Company.

More... »

Avanir, Merck announce diabetes co-promotion agreement

Thursday, August 15, 2013 12:30 PM

Avanir Pharmaceuticals has entered into an exclusive, multi-year agreement with Merck to co-promote Merck's type 2 diabetes therapies Januvia (sitagliptin) and the sitagliptin family of products in the long-term care institutional setting in the U.S.

More... »

Sanford-Burnham, Pfizer collaborate

Thursday, August 15, 2013 11:14 AM

Sanford-Burnham Medical Research Institute has signed a three-year collaboration agreement with Pfizer to identify therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering therapeutic strategies for reducing insulin resistance in obesity and diabetes.

More... »

Certara acquires Great Lakes Drug Development

Thursday, August 15, 2013 10:11 AM

Certara, a provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, has acquired drug development consultancy Great Lakes Drug Development (GLDD), based in Brighton, Mich. Both companies focus on pharmacokinetic (PK) and pharmacodynamic (PD) analysis, project management and pharmacometric modeling and simulation. GLDD focuses on early development work, while Certara’s products and services span the entire drug development continuum.

More... »